Donanemab

Tax included
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
MedChemExpress 
HY-P99859

Data sheet

Size
Multiple sizes
Reactivity
Amyloid-β
CAS
1931944-80-7